The global anti-obesity drug market is growing at a rapid clip, with Morgan Stanley analysts recently predicting that it could be worth as much as $77 billion by 2030. And leading the pack among developers of these new treatments is Denmark’s Novo Nordisk, which sells the two most popular drugs being taken for weight loss, Wegovy and Ozempic.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,